HER-2/NEU (HER2) ICD MEMORY IMMUNITY AFTER VACCINATION HER2-ICD

HER-2/NEU (HER2) ICD 疫苗接种后的记忆免疫力 HER2-ICD

• 批准号: 7379380
• 负责人: LUPE G SALAZAR
• 金额: $ 0.17万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379380
• 关键词: HER; NEU; HER2; ICD; MEMORY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite recent advances in the conventional treatment of solid tumors, patients with breast and ovarian cancer may relapse after definitive therapy because of residual microscopic disease. One approach to the eradication of residual sub-clinical disease has been the development of tumor vaccines that focus on generating tumor-specific T cell immunity. Cancer vaccine studies have now demonstrated that patients can develop tumor antigen specific immune responses post-immunization. While most cancer vaccine studies have focused on the generation of measurable immunity during active immunization, few studies have evaluated the persistence of immunity or the generation of immunologic memory. Indeed, it is the development of immunologic memory to the vaccinating antigen that would be the key to the success of a tumor vaccine to protect against relapse. Thus, we propose to determine whether patients previously immunized with a HER2 Intracellular Domain (ICD) DNA vaccine develop a memory T cell response to HER2.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。尽管实体瘤的常规治疗最近取得了进展，但乳腺癌和卵巢癌患者可能会因残留的微观疾病而在根治性治疗后复发。根除残余亚临床疾病的一种方法是开发专注于产生肿瘤特异性 T 细胞免疫的肿瘤疫苗。癌症疫苗研究现已证明，患者在免疫后可以产生肿瘤抗原特异性免疫反应。虽然大多数癌症疫苗研究都集中在主动免疫过程中产生可测量的免疫力，但很少有研究评估免疫力的持久性或免疫记忆的产生。事实上，对疫苗接种抗原的免疫记忆的发展将是肿瘤疫苗成功预防复发的关键。因此，我们建议确定之前接受过 HER2 细胞内结构域 (ICD) DNA 疫苗免疫的患者是否会对 HER2 产生记忆 T 细胞反应。